MLTX · MoonLake Immunotherapeutics
$18.19
+0.64 (+3.65%)
At close · Aug 6
Market Cap
$1.29B
Shares
73.62M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$17.55
Open$17.94
Day$17.45–18.09
52W$5.95–62.75
Avg vol 30d1.3M
Short int6.3M · 8.6% float · 5.0d
Short vol29%
Last earningsFeb 23, 2026
DataOct 2020–Aug 2026
Filing10-Q · May 11
Up next
Next earnings call
Aug 24, 2026
Est · unconfirmed
· in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Strong
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.46
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+8%
above
Price vs 50-day avg
−8%
below
RSI (14)
42
neutral
MACD trend
Negative
52-week position
20%
mid-range
Momentum
relative strength
1-month return
−8%
trailing
6-month return
+11%
trailing
YTD return
+33%
this year
Relative strength
0%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $19 › 200d $16 — 50d above 200d
Institutional flow
Accumulating
27 of 148 funds reported for Jun 30 · net +298.1K sh shares · +10 new
Insider flow
Distributing
Net -$273.3K over 90 days · 100% sells
Short interest
Falling
8.60% of float · ▼ -3.4% MoM · 5.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
148 holders — near 3-yr high, broad support
Squeeze score
69
elevated · 0–100
Fundamentals
EPS growth
−87%
Y/Y
Free cash flow
$-196.0M
Balance sheet
$260.4M
net cash
Quant / Vol
risk profile
Volatility
118%
annualized · 1-yr
Max drawdown
−90%
past year
ATR
5.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+8%
Bullish
Price vs 50-day avg
−8%
Bearish
RSI (14)
42
Neutral
MACD trend
Negative
Bearish
52-week position
20%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $19 › 200d $16 — 50d above 200d
Institutional flow
Accumulating
27 of 148 funds reported for Jun 30 · net +298.1K sh shares · +10 new
Insider flow
Distributing
Net -$273.3K over 90 days · 100% sells
Short interest
Falling
8.60% of float · ▼ -3.4% MoM · 5.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
148 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $6
Now $18 · 20%
52-wk high $63
vs 200-day avg +8%
vs 50-day avg -8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MLTX
this stock
MoonLake Immunotherapeutics
|
$1.29B | +33.2% | — | — | 8.6% |
|
ONC
BeOne Medicines Ltd.
|
$484.13B | +7.8% | +22179.2% | 744.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.89B | +6.9% | +46.2% | 28.2 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$79.13B | -0.2% | +20.8% | 19.0 | 3.4% |
|
ARGX
Argenx SE
|
$54.30B | +3.2% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MLTX | -4.5% | -8.0% | +11.2% | -4.8% | +33.2% |
| SPY | +5.5% | +3.3% | +11.3% | +3.1% | +12.9% |
| vs SPY | -10.1% | -11.2% | -0.1% | -7.9% | +20.3% |
Key facts
CIK
1821586
CUSIP
61559X104
13F (30d)
25 filings
25 filers
Visit website
Investor relations